p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.
about
Design of small molecule epigenetic modulatorsProtein lysine acetylation by p300/CBPStructured and disordered regions cooperatively mediate DNA-binding autoinhibition of ETS factors ETV1, ETV4 and ETV5.Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer.High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinomaSmall-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.Development of a nuclear morphometric signature for prostate cancer risk in negative biopsies.Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotypeCancer epigenetics: above and beyondPregnancy-induced chromatin remodeling in the breast of postmenopausal womenHigh expression of p300 is linked to aggressive features and poor prognosis of nasopharyngeal carcinoma.Regulators of gene expression as biomarkers for prostate cancerHigh expression levels of COX-2 and P300 are associated with unfavorable survival in laryngeal squamous cell carcinomaProtective effect of α-lipoic acid against radiation-induced fibrosis in mice.Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.The effect of CTB on P53 protein acetylation and consequence apoptosis on MCF-7 and MRC-5 cell lines.Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.Combination of Salermide and Cholera Toxin B Induce Apoptosis in MCF-7 but Not in MRC-5 Cell Lines.Nuclear morphometry, nucleomics and prostate cancer progressionNon-invasive biomarker in prostate carcinoma: a novel approach.Procyanidin B3, an inhibitor of histone acetyltransferase, enhances the action of antagonist for prostate cancer cells via inhibition of p300-dependent acetylation of androgen receptor.Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo.DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.Effective Quenchers Are Required to Eliminate the Interference of Substrate: Cofactor Binding in the HAT Scintillation Proximity Assay.P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancerSubcellular localization of β-arrestin1 and its prognostic value in lung adenocarcinoma.Overexpression of p300 correlates with poor prognosis in patients with cutaneous squamous cell carcinoma.PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.Expression of ERβ and its co-regulators p300 and NCoR in human transitional cell bladder cancer.
P2860
Q26850027-5BBC3F8C-B869-49CF-9B4E-A1C8BA01356FQ27021749-4E6858F0-86C5-4DBF-8F0B-8403FA5DA596Q33558203-10AAD0B0-2D7E-4FBF-BA0C-5DFA14336BC9Q34039929-CCB30D63-1FE7-4262-84DD-0ECBD9D0592EQ34499336-9B0CEB49-1AB7-43BA-AD72-F3E91A0F366CQ34692024-9110A74D-5F32-42C5-958D-BBA2D2F15E23Q34902668-CDA61845-4F0C-48EF-9BDC-4284078040B5Q35182839-C8452664-DA51-4EDD-9486-E4661FB68DF4Q35844494-E0C41C7A-3B87-409D-9177-132AE666BB34Q35954741-5F976E46-D6C5-4DF7-B936-44E8BFCF9563Q36356267-21115570-3595-46F7-8184-854D33844417Q36439912-60B0F9CE-B23E-49D0-B30D-28192630787BQ36632043-A0BE8F11-18D9-44FB-BC0B-3E08E1578284Q37085820-3503538E-065B-4EDE-BEA3-6160AE524EE0Q37102942-FDB76868-54E0-444F-803F-6FEB1BDDAA71Q37108490-7D0A3C50-7215-4DEB-9C2A-BF7A3DC6AF94Q37223691-909C1B5A-286E-4F90-9DFB-6A9DB3093C96Q37503038-10A00AC1-7E90-48AD-8B14-E903A6F27E33Q38002780-E2A43042-3FC7-4673-900D-BC068A5E92BFQ39484265-F20CBE8E-FE70-4F91-809B-0303EEE2716AQ39642888-ECE3B577-E174-42CD-B0ED-C9935A9C7AB6Q39860046-6BF2F3D1-E511-4DA5-9FD3-CA4C349B147BQ39872525-6576DC10-1AEB-4270-BABB-13CDE0189DCCQ41448658-380DBC6C-D2FA-4FFD-9E7D-E5D2094EEB44Q41816428-8FB3DE1E-F146-4B7A-A272-465C71E4E28CQ45680294-E32D69E8-C828-4C2F-9300-8B05DB58326EQ46449536-315AAD8D-D24E-4DBC-8968-66690FFC8178Q52727709-F5CE1D09-B844-41BE-9D67-D66021C51ABBQ53287498-B379F1F4-325A-43D4-BEBA-49047FDDA7CD
P2860
p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
p300 (histone acetyltransferas ...... thelia nuclear size and shape.
@ast
p300 (histone acetyltransferas ...... thelia nuclear size and shape.
@en
p300
@nl
type
label
p300 (histone acetyltransferas ...... thelia nuclear size and shape.
@ast
p300 (histone acetyltransferas ...... thelia nuclear size and shape.
@en
p300
@nl
prefLabel
p300 (histone acetyltransferas ...... thelia nuclear size and shape.
@ast
p300 (histone acetyltransferas ...... thelia nuclear size and shape.
@en
p300
@nl
P2093
P2860
P356
P1433
P1476
p300 (histone acetyltransferas ...... thelia nuclear size and shape.
@en
P2093
Cameron Marlow
Danil V Makarov
Michael C Miller
Robert W Veltri
Sumit Isharwal
P2860
P304
P356
10.1002/PROS.20772
P577
2008-07-01T00:00:00Z